Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023)
Genelux (GNLX) recorded quarterly Total Non-Current Liabilities of $1.9 million in Q4 2023, up 44.76% quarter-over-quarter from $1.3 million in Q3 2023, and down 80.74% on a YoY basis from $9.7 million in Q4 2022.
Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Genelux's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.9 million for Q4 2023.
- In Q4 2023, Total Non-Current Liabilities fell 80.74% year-over-year to $1.9 million; the TTM figure through Dec 2023 stood at $1.9 million (down 80.74% YoY), while the FY2023 annual figure was $1.9 million, down 80.74% from the prior year.
- Total Non-Current Liabilities was $1.9 million for Q4 2023 at Genelux, up from $1.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.7 million in Q4 2022 to a low of $1.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Dec 31, 2022 | 9.69 Mn |